Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CONDOR provides a single national route to evaluate new diagnostic tests for COVID-19.

The CONDOR Platform logo.The CONDOR platform is accelerating how quickly promising COVID-19 diagnostics make it into real-world use. It is evaluating new COVID-19 diagnostics in the settings they will be used, such as in GP surgeries, care homes or hospitals, as well as their performance in laboratory settings.

The CONDOR platform consists of six different workstreams – three clinical evaluation studies, and three cross cutting studies.

Clinical evaluation studies:

  1. FALCON-C19: The FALCON-C19 study covers hospital emergency departments, inpatient areas, e.g. COVID wards, acute medical units and critical care, and 'Hospital at Home Services'.
  2. CONDOR-CH: The CONDOR-CH study is looking at rapid testing specifically in care home  settings.
  3. RAPTOR-C19 is focussed on community settings, such as GP surgeries and COVID-19 testing centres

Cross cutting studies:

  1. Care Pathway Analysis: "Care pathway mapping” studies will identify where new technologies could have the most impact on patient health during the different phases of the pandemic. 
  2. Human Factors analysis: Analysing the interaction between people and technologies in real-world healthcare.
  3. Analytical performance: Evaluating which tests should be trialled in the different clinical settings and putting the right ones forward into our clinical studies.

Co-led between the University of Oxford with Manchester University’s Diagnostic and Technology Accelerator (DiTA), project partners include the University of Nottingham, NIHR MedTech and In Vitro Diagnostic Co-operatives based in Oxford, Leeds, London and Newcastle, AHSN North East and North Cumbria, and Yorkshire and Humber AHSN.

Oxford co-leads: Associate Professor Gail Hayward (CONDOR), Dr Brian Nicholson (RAPTOR C-19)

Research Groups: NIHR Community Healthcare MedTech and In Vitro Diagnostics Co-operative, Cancer Research Group

Funding: UKRI, NIHR, Asthma UK, British Lung Foundation.

Visit the CONDOR platform website here.